The story of GenZ is an inspiring tale of innovation and scientific breakthroughs. Founded by a group of top VCs in MENA and ambitious and driven scientists&engineers from diverse scientific backgrounds, GenZ Biotechnology set out on a mission to revolutionize the field of technology and make a positive impact on human health.
The journey of GenZ Biotechnology began with a vision to develop advanced diagnostic tools and therapies that could improve disease detection and treatment. The team dedicated countless hours to research and development, pushing the boundaries of scientific knowledge and exploring new possibilities from cancer to infectious diseases.
One of the pivotal moments in GenZ’s story was the discovery of a groundbreaking technology that allowed for rapid and accurate protein testing. This technology, based on cutting-edge biotechnology, mechanics and bioinformatics, enabled GenZ to develop highly sensitive and specific diagnostic tests for a wide range of diseases
As news of their breakthroughs spread, GenZ Biotechnology gained recognition in the scientific community and attracted attention from investors. With increased funding, we were able to expand our research efforts and accelerate the development of innovative biotechnological solutions.
Over the years, GenZ Biotechnology successfully launched several diagnostic tests that revolutionized the field. Our tests not only provided earlier and more accurate detection of diseases but also easy to self development kit for custom protein testing. That offers researches a uniqe state of the art solution for advance proteomics research and personalized treatment options based on a patient’s metabolic profile. This personalized medicine approach led to more effective and targeted therapies, improving patient outcomes and quality of life.
With each milestone achieved, GenZ Biotechnology continued to push the boundaries of what was possible in medicalcare. Our relentless pursuit of scientific excellence and commitment to improving human health earned them global recognition and numerous accolades.
The story of GenZ Biotechnology is a testament to the power of passion, collaboration, and scientific curiosity. By combining their expertise and embracing the latest advancements in biotechnology, the team at GenZ has made significant contributions to the field, shaping the future of medicine and paving the way for a healthier world.
How do we generate impact
Genz generates a social impact on the world by making reliable and affordable health services accessible to a larger population. Their focus on developing innovative technologies for molecular diagnostics helps to reduce inequalities in healthcare and promote early detection and prevention of diseases. By partnering with academic research projects, they also contribute to advancing scientific knowledge and improving the quality of healthcare globally. Overall, Genz’s products and services have the potential to significantly improve public health outcomes and make a positive impact on society.
GenZ is characterized by its development of a diverse range of innovative products that have significant applications in molecular diagnosis. These products introduce innovation to the market, addressing existing gaps and meeting unmet needs.
GenZ Biotechnology is committed to making reliable healthcare accessible to more people and reducing health inequalities. Its products aim to improve the accuracy and speed of disease diagnosis, which can lead to more timely treatment and better outcomes for patients.
GenZ has developed its proprietary-based tests and next-generation POCT technologies, which enable extremely reliable and fast results with a fully automatized diagnostic procedure. This provides a unique selling point in the molecular diagnostics market and makes Genz Biotechnology stand out from its competitors.
GENZ: A Revolutionary Biotech Startup Featured in Europe’s Hottest Investment Opportunities
May, 2023 We are excited to announce that GENZ, a groundbreaking biotech startup, has been selected as one of the 14 listed companies in Europe’s prestigious Venture Capital Matchmaking event for May 2023. This recognition highlights GENZ’s exceptional potential as an investment opportunity and its significant impact on the healthcare industry. Let’s dive into the… Read More »GENZ: A Revolutionary Biotech Startup Featured in Europe’s Hottest Investment Opportunities
08.11.2021 Pharmaboardroom interview with Umut Ağyüz – Founder & CEO, Genz Biotechnologyyou can reach from the link https://pharmaboardroom.com/interviews/umut-ag%cc%86yu%cc%88z-founder-ceo-genz-biotechnology/ Genz: Revolutionizing Diagnostics – An Interview with Umut Ağyüz, Founder & CEO In this exclusive interview with Umut Ağyüz, the Founder & CEO of Genz Biotechnology, we delve into the inspiring story of Genz’s inception, its mission… Read More »Pharmaboardroom Interview
DNA Weekly Interview
In an interview with DNA Weekly (link: https://www.dnaweekly.com/blog/genz-interview/), CEO Umut Ağyüz discusses the advancements and future impact of Genz Biotechnology. Genz is a biotech company focused on developing innovative and accessible diagnostic solutions. Their primary areas of focus include early cancer diagnosis and addressing new pandemics. The company has developed the GENZPRO lab-accurate point-of-care testing… Read More »DNA Weekly Interview
Elgun T, Oltulu M. Y, Gök AY, Ağyüz U, Kılıç U Determination of Rh type and gender using circulating cell-free fetal DNA in early pregnancy of Rh negative women in Turkey. Transfusion Clinique et Biologique 2023 Apr 26 Doi : 10.1016/j.tracli.2023.04.004
Ağraz M, Ağyüz U, Welch EC, Kuyumcu B, Burak MF (2022) Machine learning characterization of a novel panel for metastatic prediction in breast cancer. Glob J Perioperative Med 6(1): 005-011. DOI: 10.17352/gjpm.000011
Hayretdag C, Algedik P, Ekmekci CG, Gunal OB, Agyuz U, Yildirim H, Coskunpinar E. Determination of genetic changes in etiology of autism spectrum disorder in twins by whole-exome sequencing. Gene Reports. 2020 Feb 1:100618.
Turkdogan D., Usluer S., Akalin F., Agyuz U. and Aslan E.S., 2017. Familial early infantile epileptic encephalopathy and cardiac conduction disorder: A rare cause of SUDEP in infancy. Seizure, 50, pp.171-172.
PCT/TR2022/050481 – 25/05/2022
PCT/TR2022/051712 – 30/12/2022
Listed in Venture Capital Matchmaking May 2023 report by Major of London.
Hello Tomorrow Deep Tech Pioneer
1MillionStartups UK- Female Founders Finalist
Sanofi Pharma Turkey – PharmUp Finalist
A2030 SDG Accelerator Finalist
Hannover Plus Awards, Germany
Winner of Eurasia HIMSS’19 EurasiaStart
Forbes Turkey 38th startup in top 50
TechAnkara top 9 startup
TOBB Tepav BIOSTARTUP Mena 3rd startup
Startup Journal top 100 startups